HC Wainwright Forecasts Innate Pharma FY2030 Earnings

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) – Stock analysts at HC Wainwright issued their FY2030 earnings estimates for shares of Innate Pharma in a report issued on Tuesday, April 7th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings of $0.42 per share for the year. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock.

IPHA has been the subject of several other research reports. BTIG Research assumed coverage on shares of Innate Pharma in a research note on Thursday, March 12th. They issued a “buy” rating and a $8.00 price objective for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Innate Pharma in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Innate Pharma has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Innate Pharma Stock Performance

NASDAQ:IPHA opened at $1.45 on Thursday. The company has a fifty day moving average of $1.55 and a 200-day moving average of $1.77. Innate Pharma has a twelve month low of $1.17 and a twelve month high of $2.63.

Innate Pharma (NASDAQ:IPHA) last released its quarterly earnings data on Saturday, February 14th. The company reported ($0.18) earnings per share for the quarter. The firm had revenue of $2.41 million for the quarter.

Institutional Trading of Innate Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC bought a new stake in Innate Pharma during the 4th quarter valued at $162,000. OLD Mission Capital LLC bought a new stake in Innate Pharma during the 4th quarter valued at $50,000. Finally, Millennium Management LLC bought a new stake in Innate Pharma during the 4th quarter valued at $36,000. Institutional investors own 0.16% of the company’s stock.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.